Fungus Turns Up the Heat: How a Human Immunosuppressant Is Sparking Drug Resistance

When you think about drug resistance, the first thing that comes to mind is usually bacteria or, perhaps, a virus. Few of us imagine a fungus – especially one that isn’t even supposed to be a drug target – slipping into the same arms race. Yet that’s exactly what a new study published in Science Translational Medicine has uncovered.

Researchers from eight countries set their sights on Pneumocystis jirovecii, the tiny organism behind pneumocystis pneumonia, a serious lung infection that can hit people whose immune systems are already on thin ice. The twist? They were looking at a drug that never intended to kill the fungus: mycophenolic acid (MPA), an immunosuppressant routinely prescribed to organ‑transplant recipients to keep their bodies from rejecting the new organ.

MPA works by putting the brakes on an enzyme called IMPDH in human immune cells. It turns out the fungus carries a remarkably similar enzyme, and that similarity may be the loophole the pathogen exploited.

To get to the bottom of this, the team gathered 163 P. jirovecii samples from six different corners of the globe – China, Denmark, Germany, Japan, Switzerland and the United States. Of those, 96 came from patients who had received solid‑organ transplants and who had, at some point between 2005 and 2019, suffered from pneumocystis pneumonia. The remaining specimens served as a control group.

When the scientists sequenced the fungal IMPDH gene, a pattern began to emerge. Six mutations, which were relatively common across the dataset, showed up in a striking 86 % of the transplant‑patient samples, but only in about 13 % of the controls. In the lab, they recreated both the normal and the mutated versions of the enzyme and challenged them with MPA. The mutated enzymes were far less sensitive – they needed considerably higher concentrations of the drug to be shut down.

What’s even more intriguing is how these mutations are spread. They appeared in at least eleven distinct fungal strains and varied from one country to another, and even changed over time. That suggests the fungus isn’t passing a single resistant lineage around the world; rather, it’s independently tinkering with the same target whenever it runs into the same drug pressure.

In short, we’re seeing parallel evolution – a textbook example of different populations arriving at similar solutions when faced with the same challenge. The researchers are careful to point out that they’ve demonstrated resistance in the lab, not necessarily a clinical failure of the drug. Still, the findings raise an uncomfortable question: are we inadvertently nudging opportunistic pathogens toward resistance by using drugs that were never designed for them?

The study’s authors call for a more nuanced look at how immunosuppressants affect the broader microbial world, especially in patients who are already vulnerable. As the medical community continues to wrestle with drug resistance, this fungus‑human interaction reminds us that the battlefield is more crowded than we often think.